WestHill Financial Advisors’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $38.8K | Hold |
17,082
| – | – | 0.01% | 72 |
|
|
2025
Q1 | $10.9K | Hold |
17,082
| – | – | ﹤0.01% | 73 |
|
|
2024
Q4 | $17.6K | Hold |
17,082
| – | – | ﹤0.01% | 78 |
|
|
2024
Q3 | $20.2K | Hold |
17,082
| – | – | ﹤0.01% | 75 |
|
|
2024
Q2 | $20.8K | Hold |
17,082
| – | – | 0.01% | 70 |
|
|
2024
Q1 | $37.2K | Hold |
17,082
| – | – | 0.01% | 76 |
|
|
2023
Q4 | $26.5K | Hold |
17,082
| – | – | 0.01% | 75 |
|
|
2023
Q3 | $22K | Hold |
17,082
| – | – | 0.01% | 95 |
|
|
2023
Q2 | $29.4K | Hold |
17,082
| – | – | 0.01% | 89 |
|
|
2023
Q1 | $25.8K | Hold |
17,082
| – | – | 0.01% | 89 |
|
|
2022
Q4 | $27.3K | Hold |
17,082
| – | – | 0.01% | 91 |
|
|
2022
Q3 | $25K | Hold |
17,082
| – | – | 0.01% | 84 |
|
|
2022
Q2 | $31K | Hold |
17,082
| – | – | 0.01% | 85 |
|
|
2022
Q1 | $46K | Hold |
17,082
| – | – | 0.01% | 90 |
|
|
2021
Q4 | $74K | Hold |
17,082
| – | – | 0.02% | 89 |
|
|
2021
Q3 | $87K | Buy |
+17,082
| New | +$87K | 0.03% | 71 |
|
|
2021
Q1 | $132K | Hold |
17,082
| – | – | 0.05% | 58 |
|
|
2020
Q4 | $112K | Buy |
+17,082
| New | +$112K | 0.04% | 59 |
|